SCHEMBL9220799

SCHEMBL9220799

CCC(CO)c1ccccc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
HTT P42858 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
AGTR1 P30556 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA12 O43570 1/20 0.44
CA4 P22748 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
TSHR P16473 3/20 0.42
TP53 P04637 1/20 0.42
BCHE P06276 1/20 0.41
TYR P14679 1/20 0.41
ACHE P22303 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12157085 0.88 HTT (0.53) POLBHTTNPSR1L3MBTL1AGTR1
SCHEMBL14576458 0.85 POLB (0.49) POLBHTTNPSR1L3MBTL1AGTR1
SCHEMBL28570761 0.83 POLB (0.50) POLBHTTNPSR1L3MBTL1AGTR1
SCHEMBL28570763 0.83 POLB (0.50) POLBHTTNPSR1L3MBTL1AGTR1
SCHEMBL19003505 0.81 POLB (0.47) POLBHTTNPSR1L3MBTL1CA1
SCHEMBL9220794 0.81 POLB (0.51) POLBHTTNPSR1L3MBTL1CA1
SCHEMBL29110960 0.80 POLB (0.59) POLBHTTNPSR1L3MBTL1LMNA
SCHEMBL14576778 0.79 POLB (0.62) POLBHTTNPSR1L3MBTL1LMNA
SCHEMBL8531258 0.79 ADRA1A (0.57) HTTLMNACYP1A2CA1CA2
SCHEMBL17755320 0.79 POLB (0.62) POLBHTTNPSR1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210040049-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2021-02-11 US disclosed
US-10723708-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2020-07-28 US disclosed
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC 2018-06-21 US disclosed
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC 2018-06-21 US disclosed
EP-0511879-B1 Pyrazine derivatives OTSUKA PHARMA CO LTD (JP) 1995-03-22 EP disclosed
EP-0511879-A1 Pyrazine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723708-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 POLB 36/4885HTT 3200/4885NPSR1 4679/4885
US-20210040049-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 POLB 36/4885HTT 3200/4885NPSR1 4679/4885
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 POLB 36/4885HTT 3200/4885NPSR1 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.